
Orforglipron Oral 90 × 6mg Metabolism
Tablet format · needle-freeThe non-peptide GLP-1 agonist.
A research small molecule, not a peptide: orforglipron (LY3502970), a non-peptide agonist of the GLP-1 receptor. Oral format: 90 tablets of 6 mg, nothing to reconstitute. Stocked in France. For research use only.
- In stock in France
Ordered with its water: shipped in a magnetic box
Research Use Only (RUO) · Prohibited for human or veterinary use.
Key facts
Orforglipron (LY3502970, 883.0 g/mol) is a GLP-1 receptor agonist that is not a peptide: it is a synthetic small molecule. Peptide analogues of GLP-1 are broken down in the digestive tract; a small molecule remains intact there. That is the rationale for this class in research.
This bottle contains 90 tablets of 6 mg. Pre-measured oral format: no reconstitution, no equipment. For laboratory research use only.
Protocol and preparation
Asepsis
Disinfect surfaces and stoppers (70% alcohol).
Solvent
Draw the required volume of bacteriostatic water.
Introduction
Inject gently against the vial wall (avoid direct jet on powder).
Solubilization
Roll the vial gently. Do not shake vigorously (degradation risk).
Solution storage Once reconstituted: 2-8°C (refrigerator).
Warning Theoretical tool for chemical handling. Does not constitute medical advice.
Open the dilution calculator- The vial carries no individual label. That is our standard packaging, not a downgraded vial.
- The parcel is plain. Nothing on the outside indicates the contents or the brand name.
What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.
Technical data
- Reconstitution
- Comprimés pré-dosés, aucune reconstitution.
- Molecular formula
- C48H48F2N10O5
- Molecular weight
- 883 g/mol
- CAS number
- 2212020-52-3
- Physical form
- Comprimés oraux
- Recommended solubility
- Formulation orale pré-dosée — pas de reconstitution nécessaire
- Storage conditions
- Température ambiante, à l'abri de la lumière et de l'humidité
- Use
- Research reagent, in vitro only (RUO)
Storage & handling
Keep the bottle closed, at room temperature (15 to 25 °C), protected from light and moisture. Close the bottle after each opening and leave the desiccant sachet inside if there is one. Avoid damp rooms and heat sources. Pre-measured format: nothing to reconstitute, no equipment needed.
Mechanism of action
The GLP-1 receptor is a class B G-protein-coupled receptor. Peptide agonists bind to its large extracellular domain. Orforglipron instead sits in a pocket of the transmembrane domain, as shown by the structure obtained by cryo-electron microscopy (Kawai et al., PNAS, 2020).
The same publication describes it as a partial, biased agonist: it activates the cyclic AMP pathway through the Gs protein, with very low β-arrestin recruitment. This signalling profile, distinct from that of native GLP-1, is what makes it a tool for studying the receptor.
Studies and references
Orforglipron originated in research at Chugai Pharmaceutical and is developed by Eli Lilly. It was evaluated in phase 3 in the ACHIEVE and ATTAIN programmes. The ATTAIN-1 trial (New England Journal of Medicine, 2025; 393: 1796-1806, NCT05869903) enrolled 3,127 adults for 72 weeks and compared the molecule with placebo.
This work belongs to the company developing the molecule. The product sold here is a laboratory reagent, for research use only.
